# Neurogenic Shock

Neurogenic shock is acute distributive shock after high spinal cord injury, driven by loss of sympathetic tone and often accompanied by bradycardia. Immediate priorities are trauma resuscitation, exclusion of hemorrhage and other shock states, invasive hemodynamic monitoring, and blood-pressure augmentation while definitive spinal evaluation proceeds.

**Clinical question:** How should clinicians recognize and stabilize neurogenic shock after acute spinal cord injury?

Updated: 2026-08-21T00:28:34.574992+00:00

## What matters in practice
- Acute spinal pathology above T6 can interrupt sympathetic outflow below the lesion, producing hypotension from loss of vascular tone; reduced heart rate, cardiac output, and systemic vascular resistance may coexist. [21][23]
- In an injured patient, neurogenic shock is a diagnosis made alongside—not instead of—active evaluation and treatment for hemorrhagic and other causes of shock.
- Critical-care management described in neurosurgical literature includes MAP augmentation above 85 mm Hg for 3 to 7 days after acute spinal cord injury; the supporting source characterizes dopamine or norepinephrine as options and cautions that phenylephrine may cause reflex bradycardia. [23]
- Angiotensin II is FDA-labeled to raise blood pressure in adults with septic or other distributive shock; its recommended starting dose is 20 ng/kg/min by continuous IV infusion. Its role specifically in neurogenic shock is not established by the supplied evidence. [1][6]

## Recognize the hemodynamic syndrome and localize the lesion

Treat shock immediately while defining its mechanism.

Neurogenic shock follows acute disruption of sympathetic pathways, classically from spinal cord pathology above T6. The resulting loss of sympathetic tone below the lesion lowers vascular tone and can produce hypotension. In acute spinal cord injury, disconnected sympathetic innervation is associated with decreased heart rate, blood pressure, cardiac output, and systemic vascular resistance. [21][23]

The bedside pattern of hypotension with inappropriately low or reduced heart rate after cervical or high thoracic spinal cord injury should raise suspicion, but it should not close the diagnostic evaluation. Trauma-associated hypotension requires parallel assessment for bleeding, mechanical obstruction, myocardial dysfunction, drug effects, and sepsis when clinically plausible.
- Suspect neurogenic shock in acute cervical or thoracic spinal cord injury with hypotension and bradycardia or absent compensatory tachycardia. [21][23]
- Use the neurologic examination and spinal imaging pathway to identify injury level and structural compression requiring specialty management.
- Differentiate neurogenic shock from spinal shock: spinal shock describes transient areflexia or hyporeflexia after spinal cord injury, whereas neurogenic shock denotes hemodynamic failure from sympathetic disruption. [23]

*Hemodynamic implications of acute spinal cord injury [21][23]*

| Finding | Clinical implication |
| --- | --- |
| Injury above T6 | Loss of sympathetic tone below the lesion can cause hypotension. [21] |
| Bradycardia or low-normal heart rate during hypotension | Supports impaired sympathetic cardiac response; assess for other contributors and treat unstable bradycardia according to the clinical context. [23] |
| Low cardiac output and systemic vascular resistance | Supports a distributive hemodynamic phenotype and need for monitored resuscitation and vasopressor-based support when hypotension persists. [23] |

## Stabilize in a monitored critical-care setting

Prevent secondary spinal cord ischemia while maintaining trauma priorities.

Patients with suspected neurogenic shock after acute spinal cord injury require close hemodynamic monitoring in an ICU-level setting. A neurosurgical review describes arterial-line consideration and ICU admission to ensure blood-pressure stability during the immediate period after injury. [23]

Initial care should proceed as trauma resuscitation: secure oxygenation and ventilation, protect the spine, establish reliable vascular access, identify and control hemorrhage, and reassess perfusion after each intervention. Do not attribute refractory hypotension solely to neurogenic shock until hemorrhage and other immediately reversible causes have been actively considered.

Fluid administration may be necessary when hypovolemia is present, but persistent vasodilatory hypotension should prompt vasopressor support rather than repeated unbounded fluid loading. This distinction is especially important when reduced cardiac output, pulmonary complications, or concomitant injury limits fluid tolerance.
- Continuous ECG, frequent blood-pressure measurement, serial neurologic examinations, urine output, and repeated assessment of peripheral perfusion are appropriate during active shock management.
- Consider an arterial catheter when continuous blood-pressure targeting or frequent blood sampling is needed; this is specifically noted as potentially warranted in acute spinal cord injury care. [23]
- Involve spine surgery or neurosurgery early for unstable injury, cord compression, or a lesion requiring decompression or fixation.

*Early bedside priorities in suspected neurogenic shock*

| Priority | Action | Reason |
| --- | --- | --- |
| Spinal protection | Maintain immobilization appropriate to the suspected level of injury and obtain urgent spinal evaluation. | Further displacement or unrecognized compression may worsen neurologic injury. |
| Competing shock causes | Conduct repeated trauma-focused evaluation for hemorrhage and evaluate other shock mechanisms as indicated. | Neurogenic shock can coexist with hemorrhage or cardiopulmonary injury. |
| Hemodynamic surveillance | Use ICU-level monitoring; consider an arterial line when needed for MAP-directed management. [23] | Rapid recognition of hypotension and bradycardia supports timely escalation. |

## Use MAP augmentation selectively and document the evidence limits

Targeting is intended to support cord perfusion during the acute injury phase.

A neurosurgical review describes medical management of acute spinal cord injury with MAP augmentation above 85 mm Hg for 3 to 7 days. [23] This target should be individualized to the injury pattern, concurrent bleeding, cardiac function, arrhythmia risk, and the ability to provide invasive monitoring. The supplied search results do not provide a current formal U.S. guideline recommendation, comparative vasopressor trial data, or an evidence-based lower or upper duration threshold.

Avoid interpreting a MAP goal as a substitute for source control of bleeding, decompression when indicated, respiratory support, or definitive stabilization of the spinal injury. Reassess the need for pressors continuously as vasoplegia and bradycardia evolve.
- Document baseline and achieved MAP, vasopressor dose, heart-rate trend, perfusion markers, and complications during MAP augmentation.
- Escalate evaluation if hypotension remains disproportionate to the neurologic lesion or is accompanied by evidence of blood loss, hypoxemia, chest injury, ischemic ECG changes, or new ventricular dysfunction.
- The supplied sources support a commonly used MAP strategy but do not establish an optimal vasopressor, exact titration protocol, or outcome benefit for every acute spinal cord injury phenotype.

*Blood-pressure support statements available from supplied sources*

| Intervention | Available support | Practical limitation |
| --- | --- | --- |
| MAP augmentation | MAP greater than 85 mm Hg for 3 to 7 days is described in a neurosurgical review of acute spinal cord injury management. [23] | The supplied evidence does not provide a contemporary guideline grade, individualized target framework, or comparative efficacy data. |
| Norepinephrine or dopamine | The review identifies dopamine or norepinephrine for MAP augmentation in this setting. [23] | No dosing, comparative outcomes, or selection algorithm is provided in the supplied result. |
| Phenylephrine | The review advises dopamine or norepinephrine rather than phenylephrine because phenylephrine can cause reflex bradycardia in neurogenic shock. [23] | This is source-specific expert guidance; individual use requires hemodynamic and rhythm assessment. |

## Select vasoactive therapy by vasoplegia, chronotropy, and safety

Evidence supplied here supports principles more clearly than a definitive drug hierarchy.

For acute spinal cord injury with neurogenic shock, dopamine or norepinephrine are described as agents for MAP augmentation, with a specific caution that phenylephrine can precipitate reflex bradycardia. [23] In practice, selection should account for the degree of bradycardia, ventricular function, arrhythmia susceptibility, and the need for predominantly vasoconstrictor versus combined inotropic and chronotropic effects.

Angiotensin II is FDA-labeled as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The DailyMed label recommends a starting dose of 20 ng/kg/min by continuous IV infusion. [1][6] Neurogenic shock is a distributive state, but the supplied sources do not establish efficacy, safety, or a preferred place for angiotensin II in this specific condition; using it for neurogenic shock should therefore be considered off-label.
- Norepinephrine: described as an option for MAP augmentation after acute spinal cord injury. [23]
- Dopamine: described as an option for MAP augmentation after acute spinal cord injury. [23]
- Phenylephrine: use requires caution in neurogenic shock because reflex bradycardia is a reported concern in the supplied neurosurgical review. [23]
- Angiotensin II: FDA-labeled for septic or other distributive shock at a recommended initial continuous IV infusion of 20 ng/kg/min; neurogenic-shock use is not supported by the supplied evidence and is off-label. [1][6]

*Vasoactive agents referenced in supplied sources*

| Agent | Source-supported role | Key selection issue |
| --- | --- | --- |
| Norepinephrine | Option for MAP augmentation in acute spinal cord injury. [23] | Supplied sources do not provide dose or comparative outcomes. |
| Dopamine | Option for MAP augmentation in acute spinal cord injury. [23] | Supplied sources do not provide dose or comparative outcomes. |
| Phenylephrine | Not favored over dopamine or norepinephrine in the cited review. [23] | May cause reflex bradycardia in neurogenic shock. [23] |
| Angiotensin II | FDA-labeled vasoconstrictor for adults with septic or other distributive shock; start 20 ng/kg/min by continuous IV infusion. [1][6] | Specific neurogenic-shock evidence is absent in the supplied results; use would be off-label. |

## Pair hemodynamic rescue with injury-directed care and complication prevention

Shock management cannot be separated from definitive spinal cord injury care.

After physiologic stabilization, urgent characterization of cord compression, instability, and associated injuries directs operative and nonoperative management. The supplied sources note early decompression for cauda equina compression and emphasize critical-care admission after acute spinal injury to maintain blood-pressure stability. [23] They do not provide sufficient evidence to specify decompression timing or operative indications for every spinal injury pattern.

The same review describes supportive elements of acute spinal cord injury care, including lower-extremity compression, abdominal binder use to improve MAP, cough assistance, nutritional support, ulcer prophylaxis, rehabilitation consultation, and early mobilization. [23] Apply these measures according to injury pattern, contraindications, respiratory status, and institutional protocols.
- Assess and manage respiratory compromise aggressively, particularly with cervical injury.
- Initiate early multidisciplinary planning involving critical care, spine surgery or neurosurgery, trauma, rehabilitation, nursing, and respiratory therapy.
- Monitor for complications of immobilization and spinal cord injury, including venous thromboembolism, pulmonary complications, ileus, pressure injury, and urinary dysfunction; the supplied review identifies preventive supportive strategies but does not provide regimen-level details. [23]

*Supportive measures described for acute spinal cord injury [23]*

| Measure | Intended purpose |
| --- | --- |
| Lower-extremity compression stockings | Reduce risk of deep vein thrombosis and pulmonary embolism. [23] |
| Abdominal binder | Improve MAP. [23] |
| Cough assistance | Reduce risk of pneumonia. [23] |
| Early mobilization and rehabilitation consultation | Support recovery and reduce complications of immobility. [23] |

## Common questions

### What finding most strongly suggests neurogenic rather than hemorrhagic shock after spinal trauma?

Hypotension with bradycardia or an inappropriately absent tachycardic response after cervical or high thoracic cord injury supports neurogenic shock, reflecting loss of sympathetic tone. However, bleeding must still be actively excluded because shock mechanisms may coexist. [21][23]

### What MAP target is used in acute spinal cord injury with neurogenic shock?

A neurosurgical review describes augmenting MAP above 85 mm Hg for 3 to 7 days in acute spinal cord injury. [23] The supplied search results do not establish a universally optimal target, duration, or patient-specific escalation threshold.

### Which vasopressor is preferred in neurogenic shock?

The supplied review identifies norepinephrine or dopamine for MAP augmentation and advises them over phenylephrine because phenylephrine may cause reflex bradycardia. [23] It does not provide comparative trial evidence or dosing to establish a universal first-line agent.

### Is angiotensin II indicated for neurogenic shock?

Angiotensin II is FDA-labeled for adults with septic or other distributive shock, with a recommended initial continuous infusion of 20 ng/kg/min. [1][6] The supplied sources do not establish its role in neurogenic shock; use for that indication is off-label.

## References
1. Label: GIAPREZA- angiotensin ii injection - DailyMed — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c265d69a-3efe-4107-9a9e-e6fd3d531c48
2. Maxipime for Injection - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050679Orig1s000rev.pdf
3. 214787Orig1s010 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214787Orig1s010.pdf
4. FDA Adverse Event Reporting System Freedom of Information ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/FAERS%20Detailed%20HCQ%20100120%206953.pdf
5. 2021 First Generic Drug Approvals | FDA — www.fda.gov — https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2021-first-generic-drug-approvals
6. Label: ANGIOTENSIN II injection - DailyMed — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=727d1102-fc46-46f8-b78e-fd13f0738fe4&audience=consumer
7. 022569Orig1s000 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022569Orig1s000MedR.pdf
8. PRAMIPEXOLE DIHYDROCHLORIDE                                           0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg Tablets — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=04bf2b80-5371-4641-bbf5-e19587c0e9cf
9. CLINICAL REVIEW — www.fda.gov — https://www.fda.gov/media/130098/download
10. Subject: — www.fda.gov — https://www.fda.gov/media/192256/download
11. Efficacy and safety of phospholipid nanoparticles (VBI-S) in ... — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00009-9/fulltext
12. 2017 ACC/AHA/HRS Guideline for the Evaluation and ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2017.03.003
13. Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2018.07.072
14. 2023 Guideline for the Management of Patients With ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/STR.0000000000000436
15. 2023 ACC Expert Consensus Decision Pathway on ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2022.11.022
16. Current Concepts on the Management of Shock | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/01.CIR.16.6.1097
17. A prospective evaluation of hemodynamic management in ... — www.nature.com — https://www.nature.com/articles/sc201332
18. Modeling trajectories of routine blood tests as dynamic biomarkers for outcome in spinal cord injury — www.nature.com — https://www.nature.com/articles/s41746-025-01782-0
19. Hyponatremia in spinal cord injury patients: new insight ... — www.nature.com — https://www.nature.com/articles/sc2014240
20. Spinal cord injury: molecular mechanisms and therapeutic interventions | Signal Transduction and Targeted Therapy — www.nature.com — https://www.nature.com/articles/s41392-023-01477-6
21. Spinal Cord Anatomy and Localization | Continuum — journals.lww.com — https://journals.lww.com/continuum/fulltext/2021/02000/spinal_cord_anatomy_and_localization.4.aspx
22. Key Points for Issue | Continuum — journals.lww.com — https://journals.lww.com/continuum/fulltext/2024/02000/key_points_for_issue.21.aspx
23. Spine : Operative Neurosurgery — journals.lww.com — https://journals.lww.com/onsonline/fulltext/10.1093/ons/opz073~spine
24. Urogenital Symptoms in Neurologic Patients — journals.lww.com — https://journals.lww.com/continuum/fulltext/2017/04000/urogenital_symptoms_in_neurologic_patients.14.aspx

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.